AID Genomics

Company Overview

Snapshot

Founded in July 2018, AID Genomics operates with 51–200 employees. In May 2026, the company participated in a female entrepreneurship event at the Calcalist and Bank Leumi New York 2026 Mind the Tech conference, where its CEO discussed the company's commitment to ensuring Israeli citizens can vote in the 2026 elections.

Business overview

AID Genomics is a research and development-driven diagnostic company specializing in precision medicine-based diagnostic solutions. The company focuses on oncology, hereditary rare diseases, and infectious diseases, aiming to provide accurate diagnostics and data-driven therapy recommendations. Its core technology combines next-generation sequencing, miRNA, epigenetics, and AI-based analytical tools to deliver affordable precision medicine, primarily serving the healthcare and life sciences sectors.

Strategic signal

In May 2026, AID Genomics' CEO, Batell V. Blaish-Sultanik, spoke at the Calcalist and Bank Leumi New York 2026 Mind the Tech conference, emphasizing the company's commitment to enabling Israeli citizens to participate in the 2026 elections. This highlights AID Genomics' engagement beyond its core scientific mission, signaling a broader civic and social responsibility that could enhance its brand reputation and appeal to stakeholders interested in companies with strong ethical frameworks.

Company Intelligence Q&A

What was a significant operational change for AID Genomics in 2022?

In July 2022, AID Genomics suspended its research and development activities and terminated planned investments in Israel, resulting in the layoff of 400 employees. The company retained 150 employees to continue working under a contract with the Ministry of Health.

What product did AID Genomics develop in June 2022?

In June 2022, AID Genomics developed a digital kiosk for self-administered PCR testing for COVID-19. This kiosk allows individuals to perform tests without professional sampling, with samples sent to a laboratory for processing.

What strategic expansion did AID Genomics undertake in December 2021?

In December 2021, AID Genomics signed a deal to establish laboratories for detecting and genetically sequencing the coronavirus in Africa, with plans to expand operations into Europe, Asia, and North America. This involved redistributing resources and reducing its COVID-19 testing division activity in Israel.

What partnership did AID Genomics establish in October 2021?

In October 2021, AID Genomics donated a complete laboratory for coronavirus testing to Kazakhstan, including equipment and training for local teams. This initiative was in collaboration with Kazakhstan's National Center of Expertise (NCE) and the Israeli embassy.

What was AID Genomics' involvement in COVID-19 testing in Gaza in April 2020?

In April 2020, AID Genomics partnered with Beijing Genomics Institute (BGI) to open a laboratory in Gaza capable of conducting up to 3,000 coronavirus tests per day, with approval from the Palestinian Authority and funding from Mammoth Foundation.